Daniel Kulp, Ph.D.
The Kulp Laboratory
Associate Professor, Vaccine & Immunotherapy Center
About the Scientist
Kulp has more than 15 years of experience developing molecular design software and leading protein engineering projects. He joined Wistar from The Scripps Research Institute and International AIDS Vaccine Initiative where he was a principal scientist.
Kulp received a bachelor’s degree in Computer Science and Molecular Biology & Biochemistry from Rutgers, The State University of New Jersey, followed by a Ph.D. in Biochemistry and Molecular Biophysics from the University of Pennsylvania. He completed postdoctoral training in structure-based and experimental protein engineering at Los Alamos National Laboratory.
Lab in the News
Novel Nanoparticle SARS-CoV-2 Vaccine Combines Immune Focusing and Self-assembling Nanoparticles to Elicit More Potent ProtectionEngineered to use DNA to instruct cells to make vaccine in vivo and can be stored at room temperature, easily transported to remote locations.
Highlighting Vaccine Research at The Wistar Institute Through the Penn-CHOP-Wistar Vaccine SymposiumFrom HIV to COVID-19, Wistar scientists are at the forefront of vaccine development. Read our recap of the recent Vaccine Symposium and the impactful research in progress at the Institute.
The Kulp Laboratory
The Kulp laboratory focuses on rational vaccine and therapeutic antibody design for a variety of priority infectious diseases (e.g. Lassa Virus, HIV, Influenza) and cancer targets. The ultimate test of the lab's understanding of B cell immune responses is to design new immunogens that drive predictable antibody maturation. To that end, the lab is interested in the development and application of protein engineering methods for modifying antigen/cell receptor interfaces, antigen/antibody interfaces, antigen surface properties and core stabilization.
Jenna Karras, Ph.D.
In Vivo Assembly of Nanoparticles Achieved Through Synergy of Structure-Based Protein Engineering and Synthetic DNA Generates Enhanced Adaptive Immunity.
Xu, Z., Wise, M., Chokkalingam, N., Walker, S., Tello-Ruiz, E., Elliott, S., Perales-Puchalt, A., Xiao, P., Zhu, X., Pumroy, R., Fisher, P., Schultheis, K., Schade, E., Menis, S., Guzman, S., Andersen, H., Broderick, K., Humeau, L., Muthumani, K., Moiseenkova-Bell, V. , Schief, W., Weiner, D. B., Kulp, D. “In Vivo Assembly of Nanoparticles Achieved Through Synergy of Structure-Based Protein Engineering and Synthetic DNA Generates Enhanced Adaptive Immunity.” Adv Sci (Weinh). 2020 Feb 27;7(8):1902802. doi: 10.1002/advs.201902802. eCollection 2020 Apr.
Structure-based design of native-like HIV-1 envelope trimers to silence non-neutralizing epitopes and eliminate CD4 binding.
Kulp, D.W., Steichen, J.M., Pauthner, M., Hu, X., Schiffner, T., Liguori, A., Cottrell, C.A., Havenar-Daughton, C., Ozorowski, G., Georgeson, E., et al. ”Structure-based design of native-like HIV-1 envelope trimers to silence non-neutralizing epitopes and eliminate CD4 binding.” Nat Commun. 2017 Nov 21;8(1):1655. doi: 10.1038/s41467-017-01549-6.
HIV Vaccine Design to Target Germline Precursors of Glycan-Dependent Broadly Neutralizing Antibodies.
Steichen, J.M., Kulp, D.W., Tokatlian, T., Escolano, A., Dosenovic, P., Stanfield, R.L., McCoy, L.E., Ozorowski, G., Hu, X., Kalyuzhniy, O., et al. “HIV Vaccine Design to Target Germline Precursors of Glycan-Dependent Broadly Neutralizing Antibodies.” Immunity. 2016 Sep 20;45(3):483-496. doi: 10.1016/j.immuni.2016.08.016. Epub 2016 Sep 8.
Escolano, A., Steichen, J.M., Dosenovic, P., Kulp, D.W., Golijanin, J., Sok, D., Freund, N.T., Gitlin, A.D., Oliveira, T., Araki, T., et al. “Sequential Immunization Elicits Broadly Neutralizing Anti-HIV-1 Antibodies in Ig Knockin Mice.” Cell. 2016 Sep 8;166(6):1445-1458.e12. doi: 10.1016/j.cell.2016.07.030.
Briney, B., Sok, D., Jardine, J.G., Kulp, D.W., Skog, P., Menis, S., Jacak, R., Kalyuzhniy, O., de Val, N., Sesterhenn, F., et al. “Tailored Immunogens Direct Affinity Maturation toward HIV Neutralizing Antibodies.” Cell. 2016 Sep 8;166(6):1459-1470.e11. doi: 10.1016/j.cell.2016.08.005.
Andrew Kossenkov, Ph.D.
Assistant Professor, Vaccine & Immunotherapy Center
Gene Expression & Regulation Program, Ellen and Ronald Caplan Cancer Center
Scientific Director, Bioinformatics Facility